Bronchogen, with the single-letter sequence AEDL (Ala-Glu-Asp-Leu), is a Huvenson tissue-specific bioregulatory tetrapeptide, a small-molecule research peptide artificially synthesized based on endogenous peptide fragments in bronchial tissue. Unlike most peptides that rely on cell membrane receptors for signal transduction, this molecule's research hypothesis points to epigenetic regulation at the nuclear level, targeting the airway epithelial lineage. It is primarily used in preclinical model studies related to respiratory epithelial homeostasis, airway injury, and lung aging. Commercially available as a sterile lyophilized research raw material, it is not equivalent to a medical preparation and has not undergone extensive independent human clinical trials; its use is limited to laboratory in vitro cell and compliant animal experiments.
Its research logic does not focus on directly dilating the airways, but rather on resetting the gene expression state of bronchial epithelial cells and repairing the integrity of the mucosal barrier. In short-peptide bioregulatory systems, it is a tool molecule specifically targeting the bronchopulmonary lineage and is often compared with Chonluten in control studies.
The mechanism of action of Bronchogen demonstrates a remarkably elegant "epigenetic regulation" approach in current basic research. Its core function is not simply to suppress a symptom, but to reshape cellular behavior at its source by influencing DNA transcription pathways within the cell nucleus. In animal models and in vitro experiments, researchers have observed that it can improve the health of lung epithelial cells, promote the production of pulmonary surfactant, and effectively downregulate the expression of genes related to inflammation. Furthermore, it is believed to have a protective effect against certain gonadotropins, attempting to reverse age-related decline in lung function by reactivating aging DNA.
This tetrapeptide structure gives Bronchogen unparalleled advantages. First, its extremely small molecular weight (only 446.45 g/mol) and highly compact sequence mean that its synthesis cost is relatively low and purification is relatively easy. Second, this short sequence makes it ideal as a "research tool peptide" on high-throughput screening platforms, providing scientists with an excellent entry point for exploring the molecular mechanisms of chronic respiratory diseases such as COPD and pulmonary fibrosis.
However, as a high-purity research reagent, Bronchogen has extremely stringent requirements for storage conditions. Unopened lyophilized powder must be tightly sealed, protected from light, and stored in a freezer at -20°C or lower to maintain its stability for two to five years. Once reconstituted with sterile water or PBS buffer (with a small amount of DMSO as a pre-dissolution aid if necessary), it must be transferred to an ultra-low temperature environment of -70°C. It is strongly recommended to aliquot according to a single experimental dosage, and to absolutely avoid peptide chain degradation caused by repeated freeze-thaw cycles.
Precautions
The RUO label indicates "not for human use." Any subcutaneous/sublingual/nebulized use for personal use violates regulatory red lines. Russian-made oral capsules are subject to a different regulatory framework and do not equate to Western research-grade powder being injectable.
Reconstituted concentration as per experiment: 20mg + 2mL BAC = 10mg/mL. 100μg is drawn into 0.01mL (1 unit insulin injection). Use a low-absorbency filter and log; visually estimating the vial volume is strictly prohibited.
The COA must be ≥98% HPLC, MS-verified (confirming whether it's AEDL or ADEL), endotoxin-free, and free of excessive TFA residues; without a COA, it's considered waste powder.
Pregnancy/nursing, active pneumonia/tuberculosis/lung cancer, immunosuppression, or sensitivity to mammalian cell sources-avoid it; epithelial proliferation regulation is theoretically a risk, not proven, but don't gamble.
It ≠ bronchodilator, ≠ inhaled corticosteroid, ≠ antibiotic. Don't use it as an emergency medication for COPD/asthma exacerbations; it will cause problems.
Cautions for overlapping use: It can be used with Chonluten at different peaks or in the same cycle but at different sites; it doesn't directly conflict with systemic glucocorticoids/immunosuppressants, but phenotypic interpretation requires separate controls; combining with macrolides/quinolones doesn't affect the peptide itself, but clinical decisions shouldn't be mixed.
Redness at the injection site, transient airway itching (community-reported noise) are considered mild; persistent worsening cough, wheezing, low-grade fever, rash-discontinue use; don't try to tough it out.
In short, Bronchogen's approach is to "use a tetrapeptide to remind the aging bronchial epithelium of its identity." The concept is most complete in the field of lung axis bioregulation, but the evidence only extends to human bronchial cells, aged mice, and Russian open-label strains. Applying it to human treatment is another matter entirely. Reading Khavinson's 2014 Lung paper (NKX2-1/MUC regulation) and Kuzubova's 2015 Bull Exp Biol Med paper (COPD rat morphology) provides a more accurate picture than any online shopping guide. It's crucial to remember that Bronchogen and Chonluten are two different respiratory dipeptides with distinct functions; they are not interchangeable homologs.
Hot Tags: 99% pure bronchogen nourishing peptide cas: 857267-12-0, China 99% pure bronchogen nourishing peptide cas: 857267-12-0 manufacturers, suppliers, factory
